SCHEMBL13371674

SCHEMBL13371674

CC(C)CC(N1CCCC1=O)C(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 1/20 0.44
▸ LMNA P02545 2/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA3 P07451 1/20 0.42
▸ CA4 P22748 1/20 0.42
▸ CA6 P23280 1/20 0.42
▸ CA5A P35218 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ CA13 Q8N1Q1 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42
▸ CA5B Q9Y2D0 1/20 0.42
▸ CHRM2 P08172 1/20 0.42
▸ CHRM4 P08173 1/20 0.42
▸ CHRM5 P08912 1/20 0.42
▸ CHRM1 P11229 1/20 0.42
▸ CHRM3 P20309 1/20 0.42
▸ MEN1 O00255 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25997942 0.93 CHRM2 (0.40) PIK3CDLMNACA12CA1CA2
SCHEMBL20280516 0.88 LMNA (0.41) PIK3CDLMNACA12CA1CA2
SCHEMBL22571133 0.87 LMNA (0.44) PIK3CDLMNACA12CA1CA2
SCHEMBL14016042 0.85 LMNA (0.43) PIK3CDLMNACA12CA1CA2
SCHEMBL12344960 0.84 LMNA (0.42) PIK3CDLMNACA12CA1CA2
SCHEMBL12548433 0.82 LMNA (0.53) PIK3CDLMNACA12CA1CA2
SCHEMBL21763633 0.81 LMNA (0.44) PIK3CDLMNACA12CA1CA2
SCHEMBL9055316 0.81 LMNA (0.44) PIK3CDLMNACA12CA1CA2
SCHEMBL20283318 0.80 LMNA (0.41) PIK3CDLMNACA12CA1CA2
SCHEMBL26016415 0.80 LMNA (0.38) PIK3CDLMNACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220218687-A1 Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use STARTON THERAPEUTICS, INC. 2022-07-14 — — US disclosed
US-11046802-B2 Silicone hydrogel composition PEGAVISION CORPORATION (TW) 2021-06-29 — — US disclosed
US-20200406220-A1 Substrates, Systems, and Methods for Array Synthesis and Biomolecular Analysis VIBRANT HOLDINGS, LLC 2020-12-31 — — US disclosed
US-20200291160-A1 SILICONE HYDROGEL COMPOSITION PEGAVISION CORPORATION (TW) 2020-09-17 — — US disclosed
EP-3492652-A1 INKJET PRINTING METHOD, COLORED COMPOSITION, INKJET INK, INK CARTRIDGE, AND DYE POLYMER FUJIFILM Corporation (JP) 2019-06-05 — — EP disclosed
US-20190030491-A1 METHODS FOR PREPARING CARBON MOLECULAR SIEVE HOLLOW FIBER MEMBRANES FOR GAS SEPARATION GEORGIA TECH RESEARCH CORPORATION 2019-01-31 — — US disclosed
US-7713629-B2 Hydrophobic fluorinated polyelectrolyte complex films and associated methods FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION (US) 2010-05-11 — — US disclosed
US-20070265174-A1 Hydrophobic Fluorinated Polyelectrolyte Complex Films And Associated Methods FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2007-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220218687-A1 Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use IL2, MYD88, MALT1 PIK3CD 428/4885LMNA 2075/4885CA12 3851/4885
US-20190030491-A1 METHODS FOR PREPARING CARBON MOLECULAR SIEVE HOLLOW FIBER MEMBRANES FOR GAS SEPARATION TIMM9, TIMM50, TIMM44 PIK3CD 4310/4885LMNA 146/4885CA12 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback